Physician profile
Eric N Joseph
NPI 1699118141
$5,428.91
in general payments reported to CMS, 2019-2025
30 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $316 · 2021: $536 · 2022: $577 · 2023: $935 · 2024: $1,236 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.63 | 2021-2025 | |
| Abbott Laboratories | $597.36 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $541.15 | 2019-2025 | |
| Amgen INC. | $537.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $468.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $364.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $275.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $257.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $179.38 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $114.48 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
| Sanofi-Aventis U.S. LLC | $108.73 | 2019 | |
| Shield Therapeutics INC | $97.91 | 2023-2025 | Accrufer |
| Phathom Pharmaceuticals, INC. | $92.92 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $90.98 | 2023-2025 | Veozah |
| Boston Scientific Corporation | $87.72 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $77.45 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.82 | 2019-2024 | |
| Exact Sciences Corporation | $75.30 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $71.64 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $71.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.10 | 2022-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.73 | 2021-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $60.12 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $39.06 | 2023 | Quviviq |
| Dexcom, INC. | $32.26 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $31.87 | 2024-2025 | Zoryve |
| Vanda Pharmaceuticals INC. | $23.21 | 2019 | |
| Mylan Specialty L.P. | $22.69 | 2023 | Yupelri |
| Antares Pharma, INC. | $19.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.